Stanley T. Crooke

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Raúl D. Santos, Dirk Blom et al. · The Lancet · 2010 · 897 citations

Homozygous Familial Hypercholesterolaemia, Oxysterol, Cardiovascular Disease +7

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Nicholas J. Viney, Julian C. van Capelleveen, Richard S. Geary et al. · The Lancet · 2016 · 730 citations

Dose-ranging Trials, Pharmacology, Hyperlipidemia +7

Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents

Timothy A. Vickers, Seongjoon Koo, C. Frank Bennett et al. · Journal of Biological Chemistry · 2003 · 458 citations · Full text

Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II

Fred H. Drake, Glenn A. Hofmann, H F Bartus et al. · Biochemistry · 1989 · 414 citations

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Mark J. Graham, Richard Lee, Thomas A. Bell et al. · Circulation Research · 2013 · 364 citations · Full text